GFAP and Alzheimer disease: Informed by previous research24,25, we hypothesize that higher plasma biomarker levels of pTau-181 (AD-specific), NfL and GFAP (non-specific ADRD-related), but lower levels of Aβ42/40 (AD-specific), are associated with lower cognitive performance.